GlassScriptPhysician profile
Janny Mesa
NPI 1902469323
$4,398.63
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.39 · 2020: $102 · 2021: $1,245 · 2022: $1,439 · 2023: $1,013 · 2024: $375 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.65 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $931.87 | 2021-2023 | Austedo Xr, Austedo |
| Abbvie INC. | $928.96 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $758.78 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $633.57 | 2021-2024 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $543.79 | 2020-2023 | Rexulti, Abilify Maintena |
| Indivior INC. | $330.69 | 2021-2023 | Perseris |
| Allergan, INC. | $83.39 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.44 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $37.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.43 | 2022 | |
| Sanofi Pasteur INC. | $27.62 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.44 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.49 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janny Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.